EZH2 and neuroblastoma: The EZH2 inhibitor, tazemetostat, is currently under evaluation in pediatric patients with INI1-negative tumors or recurrent synovial sarcoma but has not been specifically investigated in patients with neuroblastoma (NCT02601937).